Literature DB >> 26056801

Utilizing knowledge from prior plans in the evaluation of quality assurance.

Carl Stanhope1, Q Jackie Wu, Lulin Yuan, Jianfei Liu, Rodney Hood, Fang-Fang Yin, Justus Adamson.   

Abstract

Increased interest regarding sensitivity of pre-treatment intensity modulated radiotherapy and volumetric modulated arc radiotherapy (VMAT) quality assurance (QA) to delivery errors has led to the development of dose-volume histogram (DVH) based analysis. This paradigm shift necessitates a change in the acceptance criteria and action tolerance for QA. Here we present a knowledge based technique to objectively quantify degradations in DVH for prostate radiotherapy. Using machine learning, organ-at-risk (OAR) DVHs from a population of 198 prior patients' plans were adapted to a test patient's anatomy to establish patient-specific DVH ranges. This technique was applied to single arc prostate VMAT plans to evaluate various simulated delivery errors: systematic single leaf offsets, systematic leaf bank offsets, random normally distributed leaf fluctuations, systematic lag in gantry angle of the mutli-leaf collimators (MLCs), fluctuations in dose rate, and delivery of each VMAT arc with a constant rather than variable dose rate.Quantitative Analyses of Normal Tissue Effects in the Clinic suggests V75Gy dose limits of 15% for the rectum and 25% for the bladder, however the knowledge based constraints were more stringent: 8.48 ± 2.65% for the rectum and 4.90 ± 1.98% for the bladder. 19 ± 10 mm single leaf and 1.9 ± 0.7 mm single bank offsets resulted in rectum DVHs worse than 97.7% (2σ) of clinically accepted plans. PTV degradations fell outside of the acceptable range for 0.6 ± 0.3 mm leaf offsets, 0.11 ± 0.06 mm bank offsets, 0.6 ± 1.3 mm of random noise, and 1.0 ± 0.7° of gantry-MLC lag.Utilizing a training set comprised of prior treatment plans, machine learning is used to predict a range of achievable DVHs for the test patient's anatomy. Consequently, degradations leading to statistical outliers may be identified. A knowledge based QA evaluation enables customized QA criteria per treatment site, institution and/or physician and can often be more sensitive to errors than criteria based on organ complication rates.

Entities:  

Mesh:

Year:  2015        PMID: 26056801     DOI: 10.1088/0031-9155/60/12/4873

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  6 in total

Review 1.  Automation in intensity modulated radiotherapy treatment planning-a review of recent innovations.

Authors:  Mohammad Hussein; Ben J M Heijmen; Dirk Verellen; Andrew Nisbet
Journal:  Br J Radiol       Date:  2018-09-04       Impact factor: 3.039

Review 2.  Internet-based computer technology on radiotherapy.

Authors:  James C L Chow
Journal:  Rep Pract Oncol Radiother       Date:  2017-09-08

3.  Automatic Segmentation of Clinical Target Volumes for Post-Modified Radical Mastectomy Radiotherapy Using Convolutional Neural Networks.

Authors:  Zhikai Liu; Fangjie Liu; Wanqi Chen; Xia Liu; Xiaorong Hou; Jing Shen; Hui Guan; Hongnan Zhen; Shaobin Wang; Qi Chen; Yu Chen; Fuquan Zhang
Journal:  Front Oncol       Date:  2021-02-16       Impact factor: 6.244

4.  IMRT QA using machine learning: A multi-institutional validation.

Authors:  Gilmer Valdes; Maria F Chan; Seng Boh Lim; Ryan Scheuermann; Joseph O Deasy; Timothy D Solberg
Journal:  J Appl Clin Med Phys       Date:  2017-08-17       Impact factor: 2.102

Review 5.  Applications and limitations of machine learning in radiation oncology.

Authors:  Daniel Jarrett; Eleanor Stride; Katherine Vallis; Mark J Gooding
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.629

6.  Optimizing efficiency and safety in external beam radiotherapy using automated plan check (APC) tool and six sigma methodology.

Authors:  Shi Liu; Karl K Bush; Julian Bertini; Yabo Fu; Jonathan M Lewis; Daniel J Pham; Yong Yang; Thomas R Niedermayr; Lawrie Skinner; Lei Xing; Beth M Beadle; Annie Hsu; Nataliya Kovalchuk
Journal:  J Appl Clin Med Phys       Date:  2019-08       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.